Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM)
- Details
- Category: Novartis
Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia. Novartis plans to launch Fanapt in the US in early 2010.
GSK's Avodart® / tamsulosin combination showed benefits for men with prostate enlargement
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that final results from a large, 4-year study showed that Avodart (dutasteride) and tamsulosin combination treatment reduced the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia* (BPH)-related surgery and reduced the risk of BPH clinical progression more than tamsulosin alone**.
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
- Details
- Category: Business
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has signed a definitive agreement to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry® (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.
Access to HIV medication
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has repeatedly and clearly stated that patents must not prevent access from life-saving drugs for HIV patients living in resource limited settings. In line with this and in order to accelerate access to anti-retroviral medicines, the company has initiated non-assert declarations in May 2007, well before the idea of the UNITAID patent pool was conceived.
GSK expands presence in China through strategic cooperation
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company (Walvax) have announced a cooperation agreement to form a long-term Joint Venture (JV) to develop and manufacture paediatric vaccines for use in China. The JV will produce vaccines for measles, mumps, and rubella (MMR) (Priorix™) and potentially other paediatric vaccines. GSK will also transfer the technology to enable the JV to manufacture the vaccines locally over time.
Sandoz launches somatropin, the first-ever Japanese biosimilar
- Details
- Category: Novartis
Sandoz announced the launch of its recombinant human growth hormone somatropin in Japan, the first-ever biosimilar to be approved and launched on the world's second largest pharmaceutical market.
More Pharma News ...
- Takeda to Establish Four Sales and Marketing Subsidiaries
- Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
- Merck Submits Application for Cladribine Tablets
- The Lilly TB Drug Discovery Initiative Announces New Collaborator
- Abbott to Acquire Solvay Pharmaceuticals Business
- Novartis bronchodilator QAB149 recommended for approval in European Union
- Results from Abbott's PROSPECT Study Provide New Insight